Cargando…

A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy

Proteins such as albumin, gelatin, casein, transferrin, and collagen are widely used as drug delivery systems. However, only albumin-based paclitaxel (PTX) formulation Abraxane(®) (PTX-albumin NPs prepared by nab-technology) has been successfully developed for treating metastatic breast cancer clini...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yongmei, Chen, Gang, Meng, Zhengjie, Gong, Guangming, Zhao, Wei, Wang, Kaikai, Liu, Tianqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691922/
https://www.ncbi.nlm.nih.gov/pubmed/31293178
http://dx.doi.org/10.1080/10717544.2019.1639846
_version_ 1783443475848495104
author Zhao, Yongmei
Chen, Gang
Meng, Zhengjie
Gong, Guangming
Zhao, Wei
Wang, Kaikai
Liu, Tianqing
author_facet Zhao, Yongmei
Chen, Gang
Meng, Zhengjie
Gong, Guangming
Zhao, Wei
Wang, Kaikai
Liu, Tianqing
author_sort Zhao, Yongmei
collection PubMed
description Proteins such as albumin, gelatin, casein, transferrin, and collagen are widely used as drug delivery systems. However, only albumin-based paclitaxel (PTX) formulation Abraxane(®) (PTX-albumin NPs prepared by nab-technology) has been successfully developed for treating metastatic breast cancer clinically due to abundant materials, simple industrial scale-up process, and well tumor-targeting ability. Hemoglobin (Hb) is another protein used for drug delivery with similar advantages. In this study, we successfully synthesized PEG-Hb nanoparticles loading with PTX based on previously well-established acid-denatured method. PEG-Hb-PTX NPs showed enhanced cellular uptake and great cellular inhibition ability in vitro. Moreover, our animal study showed that PEGylated NPs greatly accumulated in tumor tissues and exhibited excellent anticancer activity in vivo. We found that PEG-Hb-PTX NPs possess a better in vivo antitumor effect than the commercially available Taxol(®) formulation. We believe that PEG-Hb has great potential as an efficient drug delivery system for further clinic study.
format Online
Article
Text
id pubmed-6691922
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-66919222019-08-23 A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy Zhao, Yongmei Chen, Gang Meng, Zhengjie Gong, Guangming Zhao, Wei Wang, Kaikai Liu, Tianqing Drug Deliv Research Article Proteins such as albumin, gelatin, casein, transferrin, and collagen are widely used as drug delivery systems. However, only albumin-based paclitaxel (PTX) formulation Abraxane(®) (PTX-albumin NPs prepared by nab-technology) has been successfully developed for treating metastatic breast cancer clinically due to abundant materials, simple industrial scale-up process, and well tumor-targeting ability. Hemoglobin (Hb) is another protein used for drug delivery with similar advantages. In this study, we successfully synthesized PEG-Hb nanoparticles loading with PTX based on previously well-established acid-denatured method. PEG-Hb-PTX NPs showed enhanced cellular uptake and great cellular inhibition ability in vitro. Moreover, our animal study showed that PEGylated NPs greatly accumulated in tumor tissues and exhibited excellent anticancer activity in vivo. We found that PEG-Hb-PTX NPs possess a better in vivo antitumor effect than the commercially available Taxol(®) formulation. We believe that PEG-Hb has great potential as an efficient drug delivery system for further clinic study. Taylor & Francis 2019-07-11 /pmc/articles/PMC6691922/ /pubmed/31293178 http://dx.doi.org/10.1080/10717544.2019.1639846 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhao, Yongmei
Chen, Gang
Meng, Zhengjie
Gong, Guangming
Zhao, Wei
Wang, Kaikai
Liu, Tianqing
A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy
title A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy
title_full A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy
title_fullStr A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy
title_full_unstemmed A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy
title_short A novel nanoparticle drug delivery system based on PEGylated hemoglobin for cancer therapy
title_sort novel nanoparticle drug delivery system based on pegylated hemoglobin for cancer therapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691922/
https://www.ncbi.nlm.nih.gov/pubmed/31293178
http://dx.doi.org/10.1080/10717544.2019.1639846
work_keys_str_mv AT zhaoyongmei anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT chengang anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT mengzhengjie anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT gongguangming anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT zhaowei anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT wangkaikai anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT liutianqing anovelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT zhaoyongmei novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT chengang novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT mengzhengjie novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT gongguangming novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT zhaowei novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT wangkaikai novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy
AT liutianqing novelnanoparticledrugdeliverysystembasedonpegylatedhemoglobinforcancertherapy